mechanisms of malabsorption
Summary
Absorbing thiamine requires several steps to work: thiamine must be released from food, reach a healthy stretch of small intestine, be carried into intestinal cells by transporters, and then exit into the blood. Malabsorption occurs when disease or treatment disrupts one or more of these steps.
The best-documented causes are chronic alcohol use, which suppresses the intestinal thiamine transporters, and bariatric surgery, which combines reduced intake, intestinal bypass and vomiting. Other causes include loss of absorptive surface, rapid transit, drugs that block the transporters, bacterial overgrowth and coexisting nutrient deficiencies. In practice, malabsorption usually combines with poor intake or increased losses rather than acting alone.
The steps of absorption and how each can fail
1. Release from food
Phosphatases convert dietary TPP and TMP to free thiamine
Severe mucosal damage reducing brush-border enzyme activity; dietary thiaminases destroying thiamine (see GI Factors)
2. Contact with absorptive surface
Free thiamine reaches duodenum and jejunum
Surgical bypass; vomiting; rapid transit; reduced surface area
3. Apical uptake
THTR-2 and THTR-1 carry thiamine into enterocytes (saturable)
Reduced transporter expression (alcohol, inflammation); drug inhibition; genetic defects
4. Intracellular handling
Thiamine crosses the enterocyte
Experimental evidence that alcohol impairs this stage
5. Basolateral exit
THTR-1 moves thiamine into blood
Suppression by alcohol (historical evidence)
6. Colonic uptake of microbial thiamine
Colonocytes absorb bacterial thiamine and TPP
Colectomy; altered microbiota; contribution uncertain
Mechanisms in detail
Reduced transporter function
Chronic alcohol use
Reduced expression of THTR-1 and THTR-2 in intestine (and kidney); older studies also showed impaired active transport and basolateral exit
Strong: human absorption studies, animal and cell models
Drugs inhibiting THTR-2
Fedratinib, metformin and trimethoprim inhibit THTR-2 in vitro; intestinal THTR-2 is a plausible site of interaction
Strong in vitro; clinical significance established for fedratinib, unclear for others
Genetic transporter defects
SLC19A2 mutations (TRMA) reduce THTR-1 function; absorption continues via THTR-2 and passive diffusion
Strong
Inflammation
Experimental studies suggest inflammatory signals can reduce transporter expression
Limited
Loss of absorptive surface or contact time
Short bowel syndrome
Reduced length of absorptive intestine
Moderate; often combined with parenteral nutrition dependence
Coeliac disease (untreated)
Villous atrophy reduces surface area
Limited for thiamine specifically
Crohn's disease affecting the small intestine
Inflammation and resection
Limited to moderate; thiamine status findings in IBD are mixed
Chronic diarrhoea, rapid transit
Reduced contact time
Moderate, mainly physiological reasoning and case reports
Radiation enteritis, chemotherapy mucositis
Mucosal injury
Limited
Bariatric (weight-loss) surgery
Thiamine deficiency, including Wernicke encephalopathy, is well documented after bariatric surgery. Most cases occur in the first months after surgery and are associated with persistent vomiting. Contributing mechanisms include:
reduced food intake;
bypass of the duodenum and proximal jejunum in Roux-en-Y gastric bypass and biliopancreatic diversion, removing the main absorption site from the food stream;
pre-absorptive losses from vomiting;
small intestinal bacterial overgrowth in the bypassed or blind limb.
A study of patients after Roux-en-Y gastric bypass found that thiamine deficiency was associated with bacterial overgrowth and improved when the overgrowth was treated with antibiotics.
Pre-absorptive losses
Vomiting (hyperemesis gravidarum, eating disorders, gastric outlet obstruction, post-surgical complications) removes thiamine before it reaches absorptive sites. Because thiamine stores are small, prolonged vomiting can cause deficiency within weeks.
Small intestinal bacterial overgrowth (SIBO)
Bacteria in the small intestine can compete for thiamine. Some species produce thiaminases that destroy it. Evidence linking SIBO to clinical thiamine deficiency comes mainly from bariatric surgery studies and case reports. SIBO is a heterogeneous condition, and its effect on thiamine in other settings is not well characterized.
Coexisting nutritional deficiencies
Folate
Folate-deficient rats showed impaired thiamine absorption, possibly through effects on intestinal cell turnover
Limited (animal data)
Protein-energy malnutrition
Mucosal atrophy and reduced enzyme and transporter expression
Moderate
Magnesium
Does not impair absorption, but impairs conversion of absorbed thiamine to TPP
Limited (case reports)
Why alcohol is so damaging
Alcohol affects thiamine absorption in several ways:
Acute exposure inhibits active thiamine transport.
Chronic exposure lowers THTR-1 and THTR-2 messenger RNA and protein levels in intestinal cells.
Classic studies in malnourished people with alcohol use disorder showed reduced absorption of radiolabelled thiamine, which improved after abstinence and nutritional repletion.
Older work also implicated impaired basolateral exit from enterocytes.
These absorptive effects combine with poor intake, reduced hepatic storage, impaired phosphorylation and increased urinary loss (see Causes of Deficiency).
Assessing malabsorption
There is no routine clinical test of thiamine absorption. In research, absorption has been studied with radiolabelled thiamine and by comparing blood or urine levels after oral and intravenous doses. In clinical practice, malabsorption is usually inferred from the underlying condition, low thiamine status despite apparently adequate intake, or response to non-oral routes.
Routes around malabsorption (informational)
The following strategies are described in the literature. Choice of approach in any individual is a clinical decision.
Parenteral thiamine (intravenous or intramuscular)
Bypasses the gut entirely
Strong: standard in suspected Wernicke encephalopathy and severe malabsorption
High oral doses
At high luminal concentrations, passive diffusion supplements carrier-mediated uptake; absorption continues to rise with dose up to at least 1,500 mg in healthy people
Moderate: pharmacokinetic data in healthy volunteers; less data in people with malabsorption
Lipid-soluble derivatives
Absorbed largely independently of THTR-1/2
Moderate for higher blood levels; limited for clinical outcomes in malabsorption (see Thiamine Derivatives)
Treating the underlying cause
For example, abstinence from alcohol, treatment of SIBO, gluten-free diet in coeliac disease
Varies by condition
Evidence quality
Alcohol suppressing intestinal thiamine transport
Strong
Bariatric surgery as a cause of deficiency
Strong (systematic review of case reports and series)
Drug inhibition of THTR-2
Strong in vitro; variable clinical significance
SIBO contributing to deficiency
Moderate after bariatric surgery; limited elsewhere
IBD and coeliac disease
Limited to moderate; findings mixed
Folate deficiency impairing thiamine absorption
Limited (animal studies)
Open questions
How much do IBD, coeliac disease and other enteropathies reduce thiamine absorption in people, independent of intake?
Does SIBO outside the bariatric setting meaningfully affect thiamine status?
Which absorption strategy works best in people with established malabsorption? Comparative studies are lacking.
Related pages
Thiamine Transporters
GI Factors Affecting Thiamine Uptake
Thiamine Derivatives
Causes of Deficiency
References
Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochemical Journal. 2011;437(3):357–372.
Hoyumpa AM Jr. Mechanisms of thiamin deficiency in chronic alcoholism. American Journal of Clinical Nutrition. 1980;33(12):2750–2761.
Thomson AD, Baker H, Leevy CM. Patterns of ³⁵S-thiamine hydrochloride absorption in the malnourished alcoholic patient. Journal of Laboratory and Clinical Medicine. 1970;76(1):34–45.
Subramanya SB, Subramanian VS, Said HM. Chronic alcohol consumption and intestinal thiamin absorption: effects on physiological and molecular parameters of the uptake process. American Journal of Physiology: Gastrointestinal and Liver Physiology. 2010;299(1):G23–G31.
Aasheim ET. Wernicke encephalopathy after bariatric surgery: a systematic review. Annals of Surgery. 2008;248(5):714–720.
Lakhani SV, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutrition Research. 2008;28(5):293–298.
Howard L, Wagner C, Schenker S. Malabsorption of thiamin in folate-deficient rats. Journal of Nutrition. 1977;107(5):775–782.
Zhang Q, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metabolism and Disposition. 2014;42(10):1656–1662.
Liang X, et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics. 2015;12(12):4301–4310.
Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clinical Pharmacology. 2012;12:4.
Galvin R, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology. 2010;17(12):1408–1418.
Was this helpful?

